Wnt signaling pathway inhibitors currently exhibits a growing pipeline with approximately 26 drug candidates, P&S Intelligence
Wnt Signaling Pathway Inhibitors Pipeline in 2017
The study analyzed that the Wnt signaling pathway inhibitors therapeutics pipeline comprises approximately 26 drug candidates in different stages of development. Wnt or β-Catenin signaling pathway plays an important role in the development of pluripotent cells. The signaling pathway was earlier named as Wingless (Wng) in Drosophila and Int1 in the mouse. Wnt proteins consist of several glycoproteins that have conserved cysteine residues. There are 19 human Wnt genes that encode spliced isoforms. Wnt proteins bind to the Frizzled (Fz) receptors which forms the complex with low-density lipoprotein receptor-related protein (LRP).
Access Report Summary with Detailed TOC on "Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” at: https://www.psmarketresearch.com/market-analysis/wnt-signaling-pathway-inhibitors-therapeutics-pipeline-analysis
Insights on pipeline segments
According to the research findings, most of the drug candidates of the Wnt signaling pathway inhibitors are being developed as the small molecule. According to the Center for Disease Control and Prevention (CDC), more than 1.5 million cases of invasive cancer, including about 15,000 cases among children younger than 20 years, and more than 590,000 deaths from cancer, are reported every year in the U.S. The rising prevalence of cancer is a major factor driving the pipeline, since Wnt signaling pathway has been recognized in the development of cancer cells.
Positive Clinical Results of Wnt Signaling Pathway Inhibitors Therapeutics Candidates
The positive clinical results of Wnt signaling pathway inhibitors drug candidates are driving the pipeline growth. Samumed, LLC announced the successful completion of a 52-week Phase II clinical trial of its potential treatment for osteoarthritis of the knee. SM04690 is a novel, small molecule inhibitor of the Wnt signaling pathway, administered as an intra-articular injection. SM04690 appeared to be safe and well-tolerated at all dose levels studied.
Various Collaborations for Wnt Signaling Pathway Inhibitors Therapeutics Drug Development
In July 2017, Oncology Venture AB and 2X Oncology, Inc. entered into an exclusive global license agreement with Eisai Inc. for Eisai's Phase II PARP inhibitor E7449 - now called 2X-121. 2X-121 would be developed by 2X Oncology, Inc., a precision medicine company developing targeted therapeutics to address significant unmet needs in women's cancer.
Some of the key players developing drugs for the treatment of Wnt signaling pathway inhibitors therapeutics include Samumed, LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics, Inc. and others.
Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Analysis